Daily Roundup

PLS.ASX EVN.ASX CMP.ASX GDG.ASX C79.ASX

Latin Resources Schemes Become Legally Effective

Latin Resources Limited (ASX: LRS) has confirmed that the acquisition of the company by Pilbara Minerals Limited (ASX: PLS) via a share scheme of arrangement and an option scheme of arrangement is now legally effective. Latin Resources lodged an office copy of the orders made by the Supreme Court of Western Australia approving the Schemes with ASIC on 22 January 2025. The remaining key dates of the Share Scheme, Option Scheme and Demerger are provided, including the effective date, last day of trading for Latin Resources shares, record dates, and implementation dates. All dates are indicative and any changes will be announced through ASX and on the Latin Resources website. Latin Resources shareholders and optionholders are advised to contact the Latin Resources Information Line if they have any questions related to the Schemes or the Scheme Booklet.

Evolution Mining Reports December 2024 Quarterly Results

Evolution Mining Limited reported its December 2024 quarterly results, highlighting significant improvements in safety performance, record mine cash flow generation, and consistent operational delivery across its asset portfolio. The company's total recordable injury frequency (TRIF) 12-month moving average improved by 24% to 5.44, reflecting the focus on safety. The quarter saw record operating and net mine cash flows of $561 million (+31% QoQ) and $263 million (+53% QoQ), respectively, driven by production meeting plan and a higher gold price environment. All operations were cash positive before major capital investment, with Cowal, Red Lake, and Northparkes delivering strong cash flow performance. The Mungari mill expansion project continued to progress, with early commissioning works now expected in the June 2025 quarter, about nine months ahead of schedule and 6% under the original budget. The company also received regulatory approval to extend the Cowal open pit mining operations by 10 years and overall operations to 2042. Evolution remains on track to meet its FY25 guidance of 710,000 - 780,000 oz gold and 70,000 - 80,000 t copper at an AISC of $1,475 - $1,575/oz.

Compumedics signs 5-year Somfit contract with Philips

Compumedics Limited, a global medical device company, has signed a new 5-year contract with Philips to supply the Somfit device to Philips' pharmacy-based sleep program in Australia. The contract underpins approximately $3 million in SaaS revenues for Compumedics over the contract period through to 2028. Compumedics currently supplies the Somfit device to Philips, and this new contract secures Somfit as the number one choice for pharmacy-based sleep testing in Australia. Pharmacy-based sleep testing is the fastest growing segment of the Australian sleep diagnostic market, and Somfit is ideal for this environment as it requires simple and reliable equipment with minimal user expertise. Compumedics has worked with Philips since August 2023, with Philips acting as the distributor for Somfit devices and electrodes to these pharmacies. In the US market, Somfit sales have reached $1 million (USD 0.7 million) in the past 12 months, and Compumedics is well-placed to accelerate this growth with new sales resources.

Generation Development Group reports record quarterly flows

Generation Development Group has reported a record December quarter, with $250m of inflows, up 61% on the previous corresponding period. This was the highest quarter in the history of Generation Life, and December was the first month in history to exceed $100m in inflows. The company achieved its highest annual funds under management growth of 31% to $3.84b. Generation Life also recorded a 59% market share of quarterly inflows into investment bonds for the period ended September 2024. The company's investment bond net inflows of $194m for the quarter were the highest in its history. There are several initiatives planned for the second half of the financial year, including offering more tax-optimized investment options for investors and a campaign for the Investment-Linked Lifetime Annuity product, which has led to an increase in the sales pipeline.

Chrysos reports strong Q2 FY25 results

Chrysos Corporation Ltd (ASX:C79) reported strong Q2 FY25 results, with unaudited revenue of $15.3m, reflecting a 12% increase Quarter-on-Quarter (QoQ) and a 53% increase Year-on-Year (YoY). This growth was driven primarily by international revenue and sample volume growth. Sample volumes totalled 1.6m, reflecting 18% growth QoQ and 53% growth YoY. The company signed two new contracts with OceanaGold Corporation and SGS, building on four contracts in Q1 FY25 and bringing the total number of contracted units to 56. Three units were deployed during the quarter, including a second unit at the Barrick-Newmont NGM complex in Nevada, a unit in Orange, New South Wales for SGS, and Chrysos' first Alaskan-based unit, bringing the total number of deployed units to 34. The company remains well-funded to support continued PhotonAssay unit growth, with a cash position of $26.6m and $95m in undrawn debt available.